Abstract
Antiretroviral therapy (ART) retention is critical for achieving viral load suppression (VLS) among people living with HIV (PLHIV). Retention remains challenging in high-prevalence settings like Malawi. Short messaging service (SMS) interventions, particularly hybrid two-way texting (2wT), show promise in improving ART retention. We conducted a randomized control trial (RCT) at Lighthouse Trust in Lilongwe, Malawi, to evaluate the effectiveness of a hybrid 2wT system to improve early retention, appointment attendance, and VLS among new ART initiates within six months of ART initiation. After receiving routine ART initiation counseling, 452 new ART clients with mobile phones were randomized to 2wT or standard of care (SoC). The 2wT group received weekly motivational messages, appointment reminders, and had access to an open-ended SMS communication channel with healthcare workers. The SoC group received peer support at clinic visits and visit reminder phone calls. All participants were traced if they missed a clinic appointment by 14 days. Study outcomes included: retention in care (alive on ART), appointment adherence (attending within 2 days), and VLS (< 200 copies) at six months. Data from electronic medical records were analyzed using Chi-square tests and multivariable logistic regression. At six months post ART initiation, the 2wT group demonstrated significantly higher appointment adherence (59.6% vs. 46.8%, p = 0.008) and VLS (97.5% vs. 93.2%, p=0.007) compared to SoC. Among both 2wT and SoC, 91% remained in care (p=0.68). Although retention among 2wT and SoC at 6 months did not differ, 2wT clients were more likely to attend clinic visits on time and reach VLS in the first six months. The low-tech 2wT approach offers a scalable, appropriate intervention to enhance visit compliance and VLS among PLHIV with mobile phones. Implementing 2wT study over a longer time frame and among more clients would likely provide evidence for scaling 2wT more broadly.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study was registered with the Clinical Trial Registry on 9/6/2022 (NCT05531448).
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol received approval from both the Malawi National Health Sciences Research Committee (#22/10/3036) and the University of Washington, Seattle, USA, ethics review board (STUDY00010106). All participants provided written informed consent in either Chichewa or English before enrolling in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Interested researchers may contact the Human Subjects Division representative for our study at jedelson{at}uw.edu to request access to the datasets. Access to data will be restricted to those who complete data sharing agreements.
